BT
ATRA icon

Banque Transatlantique’s Atara Biotherapeutics ATRA Stock Holding History

Banque Transatlantique’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.1K Hold
176
– – ﹤0.01% 470
2026
Q1 		$906 Hold
176
– – ﹤0.01% 428
2025
Q4 		$3.18K Hold
176
– – ﹤0.01% 234
2025
Q3 		$2.52K Hold
176
– – ﹤0.01% 240
2025
Q2 		$1.37K Hold
176
– – ﹤0.01% 232
2025
Q1 		$1.04K Hold
176
– – ﹤0.01% 220
2024
Q4 		$2.33K Buy
+176
New +$1.85K ﹤0.01% 246

Other funds holding ATRA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Banque Transatlantique's ATRA Position: Q2 2026 in Review

Banque Transatlantique held its Atara Biotherapeutics (ATRA) position steady in Q2 2026 at 176 shares worth $3.1K. The position accounts for ﹤0.01% of the portfolio, ranked #470.

Banque Transatlantique first reported a position in ATRA in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.18K in Q4 2025. 21 funds tracked by Wall St. Rank hold ATRA as of Q2 2026.

  • Banque Transatlantique held 176 shares of Atara Biotherapeutics worth $3.1K as of Q2 2026.
  • Banque Transatlantique left its Atara Biotherapeutics share count unchanged in Q2 2026.
  • Atara Biotherapeutics made up ﹤0.01% of Banque Transatlantique's portfolio in Q2 2026, its #470 holding.
  • Banque Transatlantique first reported a position in Atara Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
  • Banque Transatlantique's Atara Biotherapeutics position peaked at $3.18K in Q4 2025.
  • 21 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2026.

Based on Banque Transatlantique's 13F filing for Q2 2026, filed 30 Jul 2026.